I2Pure molecular iodine kills major drug-resistant pathogens within seconds in lab tests. Examine efficacy, staining and hospital adoption barriers.
Obuprazine met the primary endpoint across three dose groups in a 363-patient Phase 2b schizophrenia study, with the strongest dose producing a 16.7-point placebo-adjusted PANSS improvement. Early symptom responses and low discontinuation rates support further development, but longer-term safety and comparative efficacy remain unproven.
Stoke Therapeutics reports STK-002 OPA1 protein gains as Phase 1 OSPREY advances. Examine the evidence, safety questions and 2027 readout.
A peer-reviewed five-year indirect comparison associates BRIUMVI with lower modeled disability progression risk than ocrelizumab and ofatumumab. The findings support TG Therapeutics' commercial evidence strategy but cannot establish head-to-head superiority.
Bristol Myers Squibb's admilparant meets Phase 3 IPF endpoint at 60 mg, but 120 mg misses. Examine efficacy, safety and FDA prospects.
Teleflex completes BIOMAG-LL enrollment in 102 patients, testing longer Freesolve magnesium scaffolds ahead of European regulatory expansion.
Johnson & Johnson reports two-year ICOTYDE psoriasis results, with over 72% achieving PASI 90. See what the data mean for treatment.
Perceive Bio completes 94-eye VOY-101 enrollment for geographic atrophy. Examine trial design, safety, competition and the 2027 readout.
BioMarin presents Voxzogo skull growth research and Phase 3 hypochondroplasia data. Examine clinical evidence, FDA reviews and 2027 prospects.
AnX Robotica reports 88.6% faster ProScan AI capsule reviews. Examine FDA evidence, diagnostic performance and why comparisons need caution.